

Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial

Kwabena Asare,^{1,2,3,4} TSION Andine,⁴ Nivashnee Naicker,² Jienchi Dorward,^{2,5} Nishanta Singh,⁶ Elizabeth Spooner,⁶ Jessica Andriesen,⁷ Farzana Osman,² Sinaye Ngcapu,^{2,8} Alain Vandormael,⁹ Adrian Mindel,² Salim S. Abdool Karim,² Linda-Gail Bekker,¹⁰ Glenda Gray,⁶ Lawrence Corey,⁷ Andrew Tomita,^{11,12} and Nigel Garrett^{1,2}

¹Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa; ²Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; ³Health Economics and HIV and AIDS Research Division, University of KwaZulu-Natal, Durban, South Africa; ⁴Department of Internal Medicine, College of Medicine, Howard University, Washington, District of Columbia, USA; ⁵Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxfordshire, United Kingdom; ⁶HIV and Other Infectious Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa; ⁷Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA; ⁸Department of Medical Microbiology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; ⁹Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany; ¹⁰The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa; ¹¹Centre for Rural Health, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa; and ¹²KwaZulu-Natal Research Innovation and Sequencing Platform, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa

Background. Alternative approaches to syndromic management are needed to reduce rates of sexually transmitted infections (STIs) in resource-limited settings. We investigated the impact of point-of-care (POC) versus central laboratory-based testing on STI treatment initiation and STI adverse event (STI-AE) reporting.

Methods. We used Kaplan-Meier and Cox regression models to compare times to treatment initiation and STI-AE reporting among HVTN702 trial participants in South Africa. *Neisseria gonorrhoeae* (NG) and *Chlamydia trachomatis* (CT) were diagnosed POC at eThekweni clinic and in a central laboratory at Verulam/Isipingo clinics. All clinics used POC assays for *Trichomonas vaginalis* (TV) testing.

Results. Among 959 women (median age, 23 [interquartile range, 21–26] years), median days (95% confidence interval [95% CI]) to NG/CT treatment initiation and NG/CT-AE reporting were 0.20 (.16–.25) and 0.24 (.19–.27) at eThekweni versus 14.22 (14.12–15.09) and 15.12 (13.22–21.24) at Verulam/Isipingo (all $P < .001$). Median days (95%CI) to TV treatment initiation and TV-AE reporting were 0.17 (.12–.27) and 0.25 (.20–.99) at eThekweni versus 0.18 (.15–.2) and 0.24 (.15–.99) at Verulam/Isipingo (all $P > .05$). Cox regression analysis revealed that NG/CT treatment initiation (adjusted hazard ratio [aHR], 39.62 [95%CI, 15.13–103.74]) and NG/CT-AE reporting (aHR, 3.38 [95%CI, 2.23–5.13]) occurred faster at eThekweni versus Verulam/Isipingo, while times to TV treatment initiation (aHR, 0.93 [95%CI, .59–1.48]) and TV-AE reporting (aHR, 1.38 [95% CI, .86–2.21]) were similar.

Conclusions. POC testing led to prompt STI management with potential therapeutic and prevention benefits, highlighting its utility as a diagnostic tool in resource-limited settings.

Keywords. sexually transmitted infections; point-of-care testing; central laboratory-based testing; treatment initiation; adverse event reporting.

Sexually transmitted infections (STIs) continue to affect large populations globally, despite the availability of effective treatment [1–4]. The World Health Organization (WHO) estimates

that 374 million new infections of curable *Neisseria gonorrhoeae* (NG), *Chlamydia trachomatis* (CT), *Trichomonas vaginalis* (TV), and *Treponema pallidum* occur annually among adults aged 15–49 years worldwide, of which 63 million (16%) are recorded in the WHO-Africa region [5].

These curable STIs are associated with pelvic inflammatory disease, ectopic pregnancy, infertility, genital ulcerations, fetal and neonatal complications (including death) [2, 4, 6–8], and human immunodeficiency virus (HIV) transmission risk [9].

Many years after the introduction of syndromic management for STI care [10], the population-level STI burden remains high in sub-Saharan Africa (SSA) [5]. Syndromic management entails the identification of STI syndromes (eg, vaginal and urethral

Received 02 August 2022; editorial decision 10 October 2022; published online 17 October 2022

Correspondence: K. Asare, School of Nursing and Public Health, Discipline of Public Health Medicine, 238 Mazisi Kunene Rd, University of KwaZulu-Natal, Durban, 4041, South Africa (kwabena.asare@outlook.com).

Clinical Infectious Diseases® 2023;76(5):881–9

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

https://doi.org/10.1093/cid/ciac824

discharge syndromes) and providing treatment to deal with the commonly suspected pathogens [1]. This approach has a low implementation cost and allows promptness in STI treatment, leading to its recommendation for resource-limited settings by the WHO in the 1990s [1]. However, due to the asymptomatic state of many STIs [1, 11, 12], particularly among women [13], and the low diagnostic accuracy of syndromic management [12, 14–16], high rates of untreated STIs and overuse of antibiotics [13] have been reported in most SSA settings [12, 14].

Diagnostic STI testing is arguably the best approach to management [17], but the gold standard, laboratory-based polymerase chain reaction (PCR) testing, usually has substantial operational costs and is hence less sustainable for resource-limited settings [1]. Moreover, central laboratory-based assays can cause delays in STI treatment initiation [18] due to long turnaround times for result availability [17, 19, 20]. Thus, a diagnostic method that possesses the strengths of diagnostic accuracy, prompt result turnaround, early treatment initiation or management, and cheaper operational costs would be ideal for clinical STI care in resource-limited settings.

Recent developments in diagnostic technologies have enabled an influx of potentially cheaper and more sensitive point-of-care (POC) assays for clinical care [21–23]. In South Africa, POC assays such as the Xpert CT/NG (Cepheid, Sunnydale, California) and OSOM TV (Sekisui Diagnostics, Lexington, Massachusetts) have demonstrated high diagnostic sensitivity (NG = 100%, CT = 100%, TV = 75.0%) and specificity (NG = 100%, CT = 97.6%, TV = 100%) when compared to standard laboratory-based PCR assays [24]. Similar findings have been recorded with different POC assays globally [25, 26]. However, it is still unclear whether POC assays' real-time diagnosis strength practically translates into earlier STI management compared to central laboratory testing to inform policy in resource-limited settings. To our knowledge, no study in SSA has yet compared POC and laboratory-based diagnostic approaches to determine their impact on early STI treatment initiation or other management outcomes. Therefore, recent calls for healthcare systems in resource-limited settings to consider POC testing as an alternative diagnostic care solution [10–12, 23] lack evidence regarding the effectiveness of POC versus laboratory-based testing on prompt STI management.

The objective of this study was to determine the relative effects of POC versus central laboratory-based testing on times to STI treatment initiation and reporting of adverse events (AEs) that were STIs in a cohort of women and men followed prospectively for 3 years in a phase 2b/3 HIV vaccine trial in South Africa.

METHODS

Study Design, Population, and Setting

The randomized, double-blind, placebo-controlled HVTN702 trial was conducted between 2017 and 2020 to assess the

efficacy of an ALVAC and bivalent subtype C gp120 HIV vaccine regimen adjuvanted with MF59 in South Africa. In brief, the trial enrolled 5400 HIV-negative adults aged 18–35 years. Of these, 2700 were assigned to vaccine and 2700 to placebo at 14 clinical research sites (CRSs). The HVTN702 vaccine regimen did not prevent HIV-1 acquisition [27].

This subanalysis included HVTN702 vaccine and placebo participants enrolled at 3 research clinics in eThekweni, Isipingo, and Verulam in KwaZulu-Natal province. These 3 clinics are based in the eThekweni metropolitan area, which ensured homogeneity of any unobserved structural factors that could confound the results. The eThekweni clinic is based in central Durban, while the Isipingo and Verulam clinics are located on the outskirts of Durban. STI testing and treatment were performed at enrollment and every 6 months afterward until study exit. The eThekweni CRS used POC assays, and the Isipingo and Verulam CRSs used a central laboratory-based system for NG/CT testing, but all 3 CRSs used POC assays for TV diagnosis. The HVTN702 trial was approved by the appropriate regulatory bodies in South Africa [27], and the Biomedical Research Ethics Committee of the University of KwaZulu-Natal, South Africa, approved this subanalysis (BREC/00003808/2022).

Study Measures and Assessments: STI Testing, Treatment Initiation, and STI-AE Reporting

Experienced trial staff at eThekweni CRS collected vaginal and cervical swabs or urine samples for CT and NG testing with the Xpert CT/NG POC assay operated on the GeneXpert system. At the Isipingo and Verulam CRSs, vaginal and cervical swabs or urine samples were transported on wet ice to a central laboratory at the South African Medical Research Council in Durban for NG/CT testing on the GeneXpert system. Specimen transport to the central laboratory was twice daily at midday and afternoon, and the results turnaround was within 72 hours from receipt of the sample. The OSOM TV assay was used for POC diagnosis of TV on collected vaginal and cervical swab samples among women. All STIs were appropriately treated based on the diagnostic test results.

HVTN702 trial participants were monitored for AEs, including AEs that were STIs. These were any AE with a confirmed diagnosis of NG, CT, or TV using a validated assay. We term these as “STI-AE(s)” throughout the manuscript. STI-AE reporting time was when the CRSs received the laboratory result. The CRSs reported all collected AEs to the trial's statistical and data management center using case report forms. All study events and timings for sample collection, treatment initiation, and STI-AE reporting were recorded based on quality assurance guidelines as part of the trial.

Statistical Analyses

All data analyses were conducted with Stata statistical package version 17 (StataCorp LLC, College Station, Texas) [28]. We

compared eThekwini CRS to Verulam/Isipingo CRSs on the study outcomes in women and men. First, we summarized and compared the demographic profiles of enrolled participants using χ^2 (for proportion) and rank-sum (for median) tests to ascertain baseline comparability. We then used χ^2 tests to compare the study outcomes, including the percentage of STI cases and times to STI treatment initiation and STI-AE reporting. We evaluated the impact of POC versus central laboratory-based testing on prompt STI treatment initiation and STI-AE reporting with time-to-event models.

The analysis time for all time-to-event models started at the time of sample collection and ended with study event occurrence (STI treatment initiation or STI-AE reporting) or censoring (study exit or the next sample collection observation during follow-up). We used the Kaplan-Meier estimate of the hazard function to compare trends in the cumulative probabilities of NG/CT treatment initiation and NG/CT-AE reporting with log-rank tests. We used Cox proportional hazard regression to determine the relative effects of POC compared to laboratory-based testing on times to NG/CT treatment initiation and NG/CT-AE reporting. We repeated the Kaplan-Meier and Cox regression analyses to compare times to TV treatment initiation and TV-AE reporting to confirm the consistency of the impact of POC testing on STI management since all CRSs used POC assays for TV testing. We performed a sensitivity analysis of the Cox models disaggregating all CRSs to identify any confounding of results due to aggregating Verulam and Isipingo CRS data.

The longitudinal design of HVTN702 yielded repeat STI testing observations per participant. We adjusted for repeated observations with robust estimation of standard errors and used Breslow method to account for tied survival times in all Cox regression models [29]. We evaluated the goodness-of-fit of the Cox regression models with proportional hazard tests using Schoenfeld residuals and adjusted models with time-varying covariate specifications when required [30, 31]. We used a 5% level of significance in all hypothesis tests.

RESULTS

Baseline Profile of Enrolled Women

A total of 959 women were enrolled and tested for STIs (NG, CT, and TV) over a median of 4 visits (interquartile range [IQR], 3–5) between March 2017 and June 2020 (median follow-up, 2.3 [IQR, 1.7–2.9] years). The baseline demographic details and STI prevalence stratified by CRS are presented in Table 1. The median age was 23 (IQR, 21–26) years, and 60.3% were <25 years old. Most women (96.4%) indicated being married or having a stable sexual partner. At enrollment into the trial, the prevalence of NG, CT, and TV were 3.3%, 19.8%, and 4.7%, respectively. Baseline characteristics of women across clinics were similar according to age categories,

educational status, race/ethnicity, and STI (NG, CT, and TV) prevalence (all $P > .05$).

Overall STI Testing, Incidence, Prevalence, Treatment Initiation, and STI-AE Reporting Among Women

The total number of STI tests performed during the trial, incidence, the percentage of positive cases, the corresponding percentage of treatment initiation, and STI-AE reporting are shown in Table 2. The overall percentage of NG, CT, and TV cases during follow-up were 3.7%, 13.5% and 3.1%, respectively. Of those diagnosed with NG, CT, and TV, 76.9%, 94.2%, and 89.7% received appropriate treatment, respectively. Some participants who were unable to wait for results did not receive treatment in the trial because they never returned for follow-up. Furthermore, 72.0%, 65.4%, and 58.1% of NG, CT, and TV diagnoses were reported as AEs. STI incidence, percentage of cases, the percentage of treatment initiations, and STI-AEs reported were similar across CRSs (all $P > .05$).

NG/CT treatment initiation and NG/CT-AE reporting were faster at eThekwini than Verulam/Isipingo CRSs (all $P < .05$). Most NG/CT cases (92.4%) at eThekwini CRS received appropriate treatment on the day of testing compared to 1.2% at Verulam/Isipingo CRSs ($P < .001$). The 7.6% of NG/CT-positive participants at the eThekwini clinic who did not initiate treatment on the day of testing were unable to wait for results but returned for treatment at a future study visit. At Verulam/Isipingo CRSs, the non-same-day NG/CT treatment initiations occurred within 2–7 days (7.0%), 8–14 days (36.6%), and after 14 days (55.2%) of sample collection.

Furthermore, 98.5% NG/CT-AEs were reported on the day of testing at eThekwini compared to 4.8% at Verulam/Isipingo CRSs ($P < .001$). At Verulam/Isipingo CRSs, the non-same-day NG/CT-AEs were reported within 2–7 days (30.9%), 8–14 days (37.1%), and after 14 days (27.2%) of sample collection. The timings of TV treatment initiation and TV-AE reporting were similar at all CRSs. Overall, 99.1% of TV treatment initiations (eThekwini, 100% vs Verulam/Isipingo, 98.7%; $P = .554$) and 100% TV-AE reporting (eThekwini, 100% vs Verulam/Isipingo, 100%) occurred on the day of testing. In addition, more NG/CT treatments were initiated during scheduled visits at eThekwini CRS compared to Verulam/Isipingo CRSs (91.8% vs 62.2%; $P < .001$). In contrast, the percentage of TV treatment initiations at scheduled visits was similar across CRSs (eThekwini, 100% and Verulam/Isipingo, 93.6%; $P = .178$).

Impact of POC Versus Central Laboratory-Based Testing on Time to STI Treatment Initiation Among Women

The impact of POC testing compared to central laboratory-based testing on trends in the cumulative probability of STI treatment initiation in women is shown in Figure 1A and 1C. Over 9781.0 person-days of observation, 572 NG/CT

Table 1. Baseline Demographic Characteristics of Enrolled Women, Stratified by Clinical Research Site

Variable	Category	Total (N = 959)	Verulam/Isipingo ^a CRSs (n = 699)	eThekwini ^b CRS (n = 260)	P Value
Age, y	Median (IQR)	23 (21–26)	23 (21–27)	23 (21–26)	.040
Age group, y	18–24	60.3 (578/959)	58.7 (410/699)	64.6 (168/260)	.083
	25–34	31.6 (303/959)	33.6 (235/699)	26.2 (68/260)	
	≥35	8.1 (78/959)	7.7 (54/699)	9.2 (24/260)	
School level completed	High school	61.8 (592/958)	61.7 (431/698)	61.9 (161/260)	.994
	Primary school	37.8 (362/958)	37.8 (264/698)	37.7 (98/260)	
	No schooling	0.4 (4/958)	0.4 (3/698)	0.4 (1/260)	
Married/stable partner	Yes	96.4 (889/922)	97.3 (651/669)	94.1 (238/253)	.018
Race/ethnicity	Black	99.6 (955/959)	99.4 (695/699)	100.0 (260/260)	.474
	White	0.3 (3/959)	0.4 (3/699)	0.0 (0/260)	
	Indian	0.1 (1/959)	0.1 (1/699)	0.0 (0/260)	
NG	Prevalence	3.3 (31/954)	3.5 (24/694)	2.7 (7/260)	.552
CT	Prevalence	19.8 (189/956)	20.6 (143/696)	17.7 (46/260)	.324
NG/CT	Prevalence	21.4 (205/958)	22.4 (156/698)	18.9 (49/260)	.240
TV ^c	Prevalence	4.7 (44/946)	5.1 (35/691)	3.5 (9/255)	.320

Data are presented as percentage (No.). Denominators that do not equal sample sizes are due to missing data. Percentages may not sum to 100 because of rounding.

Abbreviations: CRS, clinical research site; CT, *Chlamydia trachomatis*; IQR, interquartile range; NG, *Neisseria gonorrhoeae*; TV, *Trichomonas vaginalis*.

^aCentral laboratory–based testing for NG/CT was conducted at the Isipingo and Verulam CRSs.

^bPoint-of-care testing for NG/CT was conducted at the eThekwini CRS.

^cAll CRSs used point-of-care assays for TV testing.

treatments were initiated for 612 NG/CT cases (40 received no treatment in the trial due to loss to follow-up). [Figure 1A](#) illustrates that NG/CT treatment initiation occurred faster at eThekwini (median days, 0.20 [95% confidence interval {CI}, .16–.25]) compared to Verulam/Isipingo CRSs (median days, 14.22 [95% CI, 14.12–15.09]) ($P < .001$). In contrast, [Figure 1C](#) displays a near-perfect overlap in time to TV treatment initiation with 0.17 (95% CI, .12–.27) median days at eThekwini CRS versus 0.18 (95% CI, .15–.20) at Verulam/Isipingo CRSs ($P = .704$).

Based on the Cox proportional hazard regression results in [Table 3](#), the time to NG/CT treatment initiation was 39 times faster with POC testing at eThekwini CRS compared to laboratory-based testing at Verulam/Isipingo CRSs (adjusted hazard ratio [aHR], 39.62 [95% CI, 15.13–103.74]; $P < .001$), while there was no difference in the time to TV treatment initiation across the CRSs (aHR, 0.93 [95% CI, .59–1.48]; $P = .770$) after adjusting for demographic variables and study visit type. Older women (≥ 35 years) compared to younger women (18–24 years) were more likely to receive NG/CT treatment (aHR, 1.51 [95% CI, 1.12–2.06]; $P = .008$).

Impact of POC Versus Central Laboratory–Based Testing on Time to STI-AE Reporting Among Women

The impact of POC compared to central laboratory–based testing on STI-AE reporting trends among women is illustrated in [Figure 1B and 1D](#). Of the 612 NG/CT cases, 404 NG/CT-AEs were reported during 28 487.7 person-days of observation (208 were not confirmed as AEs). [Figure 1B](#) shows that the trend in NG/CT-AE reporting was faster at eThekwini CRS

(median days, 0.24 [95% CI, .19–.27]) compared to Verulam/Isipingo CRSs (median days, 15.12 [95% CI, 13.22–21.24]) ($P < .001$). In contrast, [Figure 1D](#) shows no difference in TV-AE reporting trends between eThekwini CRS (median days, 0.25 [95% CI, .20–.99]) and Verulam/Isipingo CRSs (median days, 0.24 [95% CI, .15–.99]) ($P = .388$).

The Cox proportional hazard regression results in [Table 4](#) shows that NG/CT-AE reporting was 3.38 times faster with POC testing at eThekwini CRS compared to laboratory-based testing at Verulam/Isipingo CRSs (aHR, 3.38 [95% CI, 2.23–5.13]; $P < .001$), while there was no significant difference in the time to TV-AE reporting (aHR, 1.38 [95% CI, .86–2.21]; $P = .183$) between CRSs, after adjusting for demographic variables, and study visit type.

Sensitivity Analysis With Disaggregated CRSs and Analysis in Men

The Cox regression sensitivity analysis of disaggregated CRSs showed identical outcomes between Verulam and Isipingo CRSs ([Supplementary Tables 1 and 2](#)). Furthermore, supplementary analysis among men for CT/NG treatment initiation and AE reporting showed identical findings as in women ([Supplementary Tables 3–6 and Supplementary Figure 1](#)).

DISCUSSION

This study tested the hypothesis that POC testing leads to prompt STI management compared to centralized laboratory-based testing among participants from higher-risk communities for STIs in South Africa. We found that NG/CT treatments were

Table 2. Overall Sexually Transmitted Infection (STI) Tests, Incidence, Positive Cases, Treatment Initiation, and STI Adverse Event Reporting, Stratified by Clinical Research Site

Variable	Category	Total (N = 959)	Verulam/Isipingo ^a CRSs (n = 699)	eThekwini ^b CRS (n = 260)	P Value
NG	Incidence ^c	6.7 (122/1822.9)	6.2 (80/1305.9)	8.2 (42/517)	.143
CT	Incidence ^c	24.8 (364/1471.5)	25.7 (268/1045.8)	22.6 (96/425.7)	.283
NG/CT	Incidence ^c	28.8 (406/1414.0)	29.7 (298/1005.2)	26.5 (108/408.8)	.305
TV ^d	Incidence ^c	4.9 (89/1847.1)	5.2 (67/1310.7)	4.2 (22/536.4)	.374
NG	Positive	3.7 (143/3830)	3.4 (91/2692)	4.6 (52/1138)	.076
CT	Positive	13.5 (518/3828)	13.8 (371/2692)	12.9 (147/1136)	.487
NG/CT	Positive	16.0 (612/3838)	16.0 (432/2700)	15.8 (180/1138)	.888
TV	Positive	3.1 (117/3784)	3.3 (87/2656)	2.7 (30/1128)	.317
NG	Treatments initiated	76.9 (110/143)	80.2 (73/91)	71.2 (37/52)	.216
CT	Treatments initiated	94.2 (488/518)	93.3 (346/371)	96.6 (142/147)	.143
NG/CT	Treatments initiated	93.5 (572/612)	93.1 (402/432)	94.4 (170/180)	.526
TV	Treatments initiated	89.7 (105/117)	89.7 (78/87)	90.0 (27/30)	.957
Time to NG treatment initiation after sample collection	Same day	31.8 (35/110)	1.4 (1/73)	91.9 (34/37)	<.001
	2–7 d	6.4 (7/110)	6.9 (5/73)	5.4 (2/37)	
	8–14 d	30.9 (34/110)	45.2 (33/73)	2.7 (1/37)	
	After 14 d	30.9 (34/110)	46.6 (34/73)	0.0 (0/37)	
Time to CT treatment initiation after sample collection	Same day	27.9 (136/488)	1.5 (5/346)	92.3 (131/142)	<.001
	2–7 d	7.0 (34/488)	7.5 (26/346)	5.6 (8/142)	
	8–14 d	25.2 (123/488)	35.3 (122/346)	0.7 (1/142)	
	After 14 d	40.0 (195/488)	55.8 (193/346)	1.4 (2/142)	
Time to NG/CT treatment initiation after sample collection	Same day	28.3 (162/572)	1.2 (5/402)	92.4 (157/170)	<.001
	2–7 d	6.6 (38/572)	7.0 (28/402)	5.9 (10/170)	
	8–14 d	25.9 (148/572)	36.6 (147/402)	0.6 (1/170)	
	After 14 d	39.2 (224/572)	55.2 (222/402)	1.2 (2/170)	
Type of study visit at which NG/CT treatments were initiated	Scheduled	71.0 (406/572)	62.2 (250/402)	91.8 (156/170)	<.001
	Unscheduled	29.0 (166/572)	37.8 (152/402)	8.2 (14/170)	
Time to TV treatment initiation after sample collection	Same day	99.1 (104/105)	98.7 (77/78)	100.0 (27/27)	.554
	2–7 d	0.0 (0/0)	0.0 (0/0)	0.0 (0/0)	
	8–14 d	1.0 (1/105)	1.3 (1/78)	0.0 (0/27)	
	After 14 d	0.0 (0/0)	0.0 (0/0)	0.0 (0/0)	
Type of study visit at which TV treatments were initiated	Scheduled	95.2 (100/105)	93.6 (73/78)	100.0 (27/27)	.178
	Unscheduled	4.8 (5/105)	6.4 (5/78)	0.0 (0/27)	
NG-AEs reported	Yes	72.0 (103/143)	67.0 (61/91)	80.8 (42/52)	.078
CT-AEs reported	Yes	65.4 (339/518)	63.3 (235/371)	70.8 (104/147)	.110
NG/CT-AEs reported	Yes	66.0 (404/612)	63.0 (272/432)	73.3 (132/180)	.014
TV-AEs reported	Yes	58.1 (68/117)	56.3 (49/87)	63.3 (19/30)	.502
Time to NG-AE reporting after sample collection	Same day	44.7 (46/103)	8.2 (5/61)	97.6 (41/42)	<.001
	2–7 d	15.5 (16/103)	24.6 (15/61)	2.4 (1/42)	
	8–14 d	25.2 (26/103)	42.6 (26/61)	0.0 (0/42)	
	After 14 d	14.6 (15/103)	24.6 (15/61)	0.0 (0/42)	
Time to CT-AE reporting after sample collection	Same day	36.6 (124/339)	8.5 (20/235)	100 (104/104)	<.001
	2–7 d	22.4 (76/339)	32.3 (76/235)	0.0 (0/104)	
	8–14 d	23.9 (81/339)	34.5 (81/235)	0.0 (0/104)	
	After 14 d	17.1 (58/339)	24.7 (58/235)	0.0 (0/104)	
Time to NG/CT-AE reporting after sample collection	Same day	35.4 (143/404)	4.8 (13/272)	98.5 (130/132)	<.001
	2–7 d	21.0 (85/404)	30.9 (84/272)	0.8 (1/132)	
	8–14 d	25.0 (101/404)	37.1 (101/272)	0.0 (0/132)	
	After 14 d	18.6 (75/404)	27.2 (74/272)	0.8 (1/132)	
Type of study visit at which NG/CT-AEs were reported	Scheduled	97.5 (394/404)	97.1 (264/272)	98.5 (130/132)	.387
	Unscheduled	2.5 (10/404)	2.9 (8/272)	1.5 (2/132)	
Time to TV-AE reporting after sample collection	Same day	100.0 (68/68)	100.0 (49/49)	100.0 (19/19)	
	2–7 d	
	8–14 d	
	After 14 d	

Table 2. Continued

Variable	Category	Total (N = 959)	Verulam/Isipingo ^a CRSs (n = 699)	eThekwini ^b CRS (n = 260)	P Value
Type of study visit at which TV-AEs were reported	Scheduled	98.5 (67/68)	98.0 (48/49)	100 (19/19)	.530
	Unscheduled	1.5 (1/68)	2.0 (1/49)	0.0 (0/19)	

Incidence data are presented as incidence rate (number of new cases/PYs). The other data are presented as percentage (number of observations during follow-up including repeat testing/number of women). Denominators that do not equal sample sizes are due to missing data. Percentages may not sum to 100 because of rounding.

Abbreviations: AE, adverse event; CRS, clinical research site; CT, *Chlamydia trachomatis*; NG, *Neisseria gonorrhoeae*; PY, person-years; TV, *Trichomonas vaginalis*.

^aCentral laboratory-based testing for NG/CT was conducted at the Isipingo and Verulam CRSs.

^bPoint-of-care (POC) testing for NG/CT was conducted at the eThekwini CRS.

^cIncidence rate was calculated as the number of new cases per 100 PYs.

^dAll CRSs used POC assays for TV testing.




Figure 1. Kaplan-Meier cumulative probability graphs displaying the effects of point-of-care (POC) versus central laboratory-based testing on sexually transmitted infection (STI) treatment initiation and STI adverse event (AE) reporting after sample collection for testing among women. *A* and *B* compare the times to *Neisseria gonorrhoeae* (NG)/*Chlamydia trachomatis* (CT) treatment initiation and NG/CT-AE reporting between clinical research sites (CRSs) that used either POC (eThekwini) or central laboratory-based testing (Verulam and Isipingo [V/I]). *C* and *D* compare the same groups of CRSs on the times to *Trichomonas vaginalis* (TV) treatment initiation and TV-AE reporting tested with POC assays at all CRSs. Median time in days (95% confidence interval [CI]) and log-rank test *P* values: *A*, V/I CRSs, 14.22 (14.12–15.09), eThekwini CRS, 0.20 (.16–.25), *P* < .001. *B*, V/I CRSs, 15.12 (13.22–21.24), eThekwini CRS, 0.24 (.19–.27), *P* < .001. *C*, V/I CRS, 0.18 (.15–.20), eThekwini CRS, 0.17 (.12–.27), *P* = .704. *D*, V/I CRSs, 0.24 (.15–.99), eThekwini CRS, 0.25 (.20–.99), *P* = .388.

Table 3. Cox Proportional Hazard Regression for the Impact of Point-of-Care Versus Central Laboratory–Based Testing on Time to Sexually Transmitted Infection Treatment Initiation Among Women

Variable	Category	Model A: NG/CT Outcome			Model B: TV ^a Outcome		
		Treatments/PD	aHR (95% CI)	P Value	Treatments/PD	aHR (95% CI)	P Value
Age group, y	18–24	413/8913.7	1		55/1312.2	1	
	25–34	138/3080.6	1.02 (.83–1.25)	.840	37/174.9	1.48 (.96–2.29)	.075
	≥35	21/230.4	1.51 (1.12–2.06)	.008	13/4.4	1.05 (.65–1.68)	.844
School level completed	High school	354/7786.9	1		59/1208.1	1	
	Primary school	216/4341.4	1.16 (.45–2.98)	.753	44/460.3	0.99 (.66–1.47)	.955
	No school	2/96.4	1.21 (.47–3.13)	.689	2/0.3	0.96 (.61–1.51)	.863
CRS ^b	Verulam/Isipingo ^c	402/11 396.3	1		78/1124.0	1	
	eThekwini ^d	170/828.3	39.62 (15.13–103.74)	<.001	27/534.8	0.93 (.59–1.48)	.770
Study visit type at which STI treatments were initiated ^b	Scheduled	406/9430.6	1		100/1634.9	1	
	Unscheduled	166/2794.1	0.76 (.52–1.11)	.152	5/33.9	0.71 (.38–1.32)	.281

Denominators that do not equal the sample sizes are due to missing data.

Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; CRS, clinical research site; CT, *Chlamydia trachomatis*; NG, *Neisseria gonorrhoeae*; PD, person-days; STI, sexually transmitted infection; TV, *Trichomonas vaginalis*.

^aAll CRSs used point-of-care (POC) assays for TV testing.

^bVariable specified as a time-varying covariate in Model A to satisfy proportional hazard assumption. Model B satisfied the proportional hazard assumption (Schoenfeld test $P = .1570$).

^cCentral laboratory–based testing for NG/CT was conducted at the Isipingo and Verulam CRSs.

^dPOC testing for NG/CT was conducted at the eThekwini CRS.

Table 4. Cox Proportional Hazard Regression for the Impact of Point-of-Care Versus Central Laboratory–Based Testing on Time to Sexually Transmitted Infection Adverse Event Reporting Among Women

Variable	Category	Model A: NG/CT Outcome			Model B: TV ^a Outcome		
		AEs Reported/PD	aHR (95% CI)	P Value	AEs Reported/PD	aHR (95% CI)	P Value
Age group in y	18–24	302/19 938.0	1		34/3567.4	1	
	25–34	94/7049.9	0.96 (.77–1.2)	.705	26/1453.8	1.53 (.96–2.43)	.074
	≥35	8/1499.9	0.46 (.22–.95)	.035	8/820.9	0.95 (.52–1.73)	.871
School level completed	High school	249/17 610.0	1		37/3705.0	1	
	Primary school	154/10 730.4	1.84 (.43–7.93)	.413	30/2096.3	1.79 (1.12–2.86)	.014
	No school	1/147.4	1.91 (.44–8.22)	.386	1/113.3	2.00 (1.36–2.93)	<.001
CRS ^b	Verulam/Isipingo ^c	272/22 453.1	1		49/4384.0	1	
	eThekwini ^d	132/6034.5	3.38 (2.23–5.13)	<.001	19/1461.8	1.38 (.86–2.21)	.183
Study visit type at which STI-AEs were reported	Scheduled	394/28 346.2	1		67/5914.4	1	
	Unscheduled	10/141.6	1.76 (1.22–2.54)	.002	1/0.3	0.99 (.67–1.46)	.960

Denominators that do not equal the sample sizes are due to missing data.

Abbreviations: AE, adverse event; aHR, adjusted hazard ratio; CI, confidence interval; CRS, clinical research site; CT, *Chlamydia trachomatis*; NG, *Neisseria gonorrhoeae*; PD, person-days; STI, sexually transmitted infection; TV, *Trichomonas vaginalis*.

^aAll CRSs used point-of-care (POC) assays for TV testing.

^bVariable specified as a time-varying covariate in Model A to satisfy proportional hazard assumption. Model B satisfied the proportional hazard assumption (Schoenfeld test $P = .4881$).

^cCentral laboratory–based testing for NG/CT was conducted at the Isipingo and Verulam CRSs.

^dPOC testing for NG/CT was conducted at the eThekwini CRS.

initiated 39 times faster, and NG/CT-AEs reported 3.4 times faster, in women when POC testing was used. When we compared TV management, the POC testing effects extended to the research clinics that used central laboratory testing for NG/CT but POC testing for TV, indicating that the findings were due to testing modalities such as result turnaround times rather than other procedures or processes at the clinics. The incidence of STIs was consistent with results from another study

among women in KwaZulu-Natal that reported 15 cases per 100 person-years for chlamydia, gonorrhea, syphilis, or trichomoniasis [32]. Therefore, our results highlight the importance of POC testing as a suitable and effective diagnostic care solution that can improve STI care outcomes and reduce disease burden in South Africa and other endemic resource-limited settings.

Some studies in SSA [33, 34] and globally [19, 20] have evaluated the effects of individual testing approaches (POC or

central laboratory based) on prompt STI treatment initiation, usually without reference to a gold standard. Consistent with our findings, a study in South Africa recorded 91.9% same-day STI (CT, NG, TV) treatment initiations with POC testing in women [33]. Another South African study found that despite the availability of 63.9% of CT-positive results within 72 hours after sample collection, treatment was only provided for 56% within 7 days, 92.2% within 14 days, and 97.5% within 28 days [19].

Our study has added evidence by determining the relative effects of the 2 current etiological testing approaches on prompt STI management. Based on the argument that the effectiveness of a diagnostic test depends on the likelihood of leading to early and accurate treatment [35], our findings suggest that POC testing is a clinically more effective approach to central laboratory-based testing for prompt STI management. Furthermore, our results underscore additional practical and potential cost implications for STI/HIV research institutions and health system stakeholders that could lead to a rethink of STI testing approaches. Same-day STI management reduced waiting times and return visits by 91.8%, simplified trial conduct, and benefited trial participants by preventing unnecessary clinic visits. Extrapolated to a healthcare system, the POC testing intervention could potentially reduce the burden on primary healthcare and STI clinics and result in healthcare savings while at the same time improving STI care [24, 36, 37]. Compared to the syndromic management approach, POC testing could also lead to prompt STI management with better diagnostic accuracy, reducing STI burden and related complications, reinfections, drug resistance, and the risk of HIV transmission.

Our study had some limitations. First, the HVTN702 trial population included a large proportion of women (70%) [27], which is why we focused the analysis on women. Nevertheless, the supplementary analysis confirmed almost identical results for men in the study. Second, our study did not retain the randomized design of the HVTN702 trial, as participants were randomized to receive a vaccine and not an STI testing approach. While baseline characteristics were broadly similar, we cannot rule out the effects of unmeasured confounding variables. However, the almost identical results of the early TV management with POC testing at all CRSs and the Cox regression sensitivity analyses that showed no difference in effect sizes between Verulam and Isipingo clinics further strengthen the validity of our findings.

In conclusion, POC testing led to prompt STI management in a trial setting in South Africa, where such evidence is most needed for decision making. Our study provides strong evidence to consider POC testing when strengthening STI care systems in resource-limited settings. However, cost, waiting times, diagnostic platforms, and error rates are essential practical issues when implementing POC testing for STI care, particularly in resource-limited settings. POC assays are not

necessarily cheaper [38], but evidence shows that they are relatively cost-effective for STI care compared to standard laboratory-based approaches [22]. Furthermore, depending on the diagnostic platform and the larger volume of testing expected outside a research setting, waiting times could be prolonged with POC testing. Moreover, POC testing can be prone to errors since it is often conducted by nonlaboratory staff, and some studies have estimated error rates of up to 0.65%, mostly occurring at the analytical phase of the testing process [39]. Recognizing these potential practical challenges, the WHO developed the ASSURED (affordable, sensitive, specific, user-friendly, rapid, equipment-free, delivered) criteria [40] that describe key features of an ideal POC assay. To improve decision making in resource-limited settings, further evidence is needed on the feasibility and cost-effectiveness of POC testing models for STI care in underresourced rural and nontrial settings, as the 3 clinics in this study were well-resourced trial sites in central/urban areas conducive to the effortless implementation of POC testing.

Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Author contributions. K. A., T. A., A. T., and N. G. designed the study and are responsible for the overall content of the manuscript. K. A. performed the statistical analyses and wrote the draft manuscript. All authors critically reviewed and approved the final submitted version.

Acknowledgments. The authors are grateful to all HVTN702 trial participants for their contributions to this research and thank the HVTN702 study team at the Isipingo, Verulam, and eThekweni clinical research sites in KwaZulu-Natal, South Africa, for their contributions to this study.

Financial support. The HVTN702 trial was supported by National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) (grant numbers HHSN272201300033C and HHSN272201600012C; the Bill and Melinda Gates Foundation (BMGF) (Global Health grant number OPP1017604) and NIAID for the manufacture and release of the gp120 clinical-grade material; and the US Public Health Service (grant numbers UM1 AI068614, UM1 AI068635, and UM1 AI068618). The South African Medical Research Council supported its affiliated research sites. K. A. was supported by a HEARD scholarship with funding from the Swedish International Development Cooperation Agency. T. A. was supported by the HIV Vaccines Trial Network's (HVTN) Research and Mentorship Program. J. D. is funded by the Wellcome Trust PhD Programme for Primary Care Clinicians (216421/Z/19/Z). For the purpose of open access, J. D. has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. J. A. reports support from the NIH (grant number UM1AI068635, funding provided to Fred Hutchinson Cancer Research Center).

Potential conflicts of interest. S. S. A. K. reports grants or contracts from the NIH (1U54TW012041 and 2UM1AI069469, paid to institution), the South African Medical Research Council (cooperative agreement paid to institution), the National Research Foundation/Department of Science and Technology (UID 96354, paid to institution), the US Agency for International Development/Right to Care (cooperative agreement 72067418CA00029, paid to institution), IQRAA Trust (paid to institution),

and European and Developing Countries Clinical Trials Partnership (RIA2017S-2008, paid to institution); received honoraria for participation in the Sanofi medical advisory committee on COVID-19 vaccines (paid to institution); and is a member of the World Health Organization science council (unpaid participation), a member of the BMFG scientific advisory committee (meeting honorarium paid to author), and Vice-President of the International Science Council (unpaid participation). G. G. reports grants from NIH, and funding and support for attending meetings and/or travel from HVTN. J. D. is co-principal investigator of the PHILA and POWER trials of point-of-care HIV viral load testing; Cepheid provided GeneXpert platforms and HIV-1 viral load cartridges for these studies at no cost. A. T. reports a grant from the UK Global Challenge Research Fund (MR/T029803/1, paid to institution). All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

- World Health Organization. Guidelines for the management of sexually transmitted infections. Available at: https://apps.who.int/iris/bitstream/handle/10665/42782/9241546263_eng.pdf?sequence=1. Accessed 23 June 2022.
- Centers for Disease Control and Prevention. Detailed STD facts—gonorrhea. Available at: <https://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea-detailed.htm>. Accessed 23 June 2022.
- Centers for Disease Control and Prevention. Detailed STD facts—chlamydia. Available at: <https://www.cdc.gov/std/chlamydia/stdfact-chlamydia-detailed.htm>. Accessed 23 June 2022.
- Centers for Disease Control and Prevention. Trichomoniasis—CDC fact sheet. Available at: <https://www.cdc.gov/std/trichomonas/stdfact-trichomoniasis.htm>. Accessed 23 June 2022.
- World Health Organization (WHO). Global health sector strategy on sexually transmitted infections 2016–2021. Geneva, Switzerland: WHO, 2016.
- Weström L, Joesoef R, Reynolds G, Hagdu A, Thompson SE. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. *Sex Transm Dis* 1992; 19:185–92.
- Centers for Disease Control and Prevention. Syphilis—CDC fact sheet (detailed). Available at: <https://www.cdc.gov/std/syphilis/stdfact-syphilis-detailed.htm>. Accessed 23 June 2022.
- Kaida A, Dietrich JJ, Laher F, et al. A high burden of asymptomatic genital tract infections undermines the syndromic management approach among adolescents and young adults in South Africa: implications for HIV prevention efforts. *BMC Infect Dis* 2018; 18:499.
- Centers for Disease Control and Prevention. STDs and HIV—CDC fact sheet. Available at: <https://www.cdc.gov/std/hiv/stdfact-std-hiv-detailed.htm#foot1>. Accessed 11 April 2022.
- Garrett NJ, Osman F, Maharaj B, et al. Beyond syndromic management: opportunities for diagnosis-based treatment of sexually transmitted infections in low- and middle-income countries. *PLoS One* 2018; 13:e0196209.
- Garrett NJ, McGrath N, Mindel A. Advancing STI care in low/middle-income countries: has STI syndromic management reached its use-by date? *Sex Transm Infect* 2017; 93:4–5.
- Mlisana K, Naicker N, Werner L, et al. Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. *J Infect Dis* 2012; 206:6–14.
- Hawkes S, Morison L, Foster S, et al. Reproductive-tract infections in women in low-income, low-prevalence situations: assessment of syndromic management in Matlab, Bangladesh. *Lancet* 1999; 354: 1776–81.
- Barry MS, Ba Diallo A, Diadihou M, et al. Accuracy of syndromic management in targeting vaginal and cervical infections among symptomatic women of reproductive age attending primary care clinics in Dakar, Senegal. *Trop Med Int Health* 2018; 23:541–8.
- Tann CJ, Mpairwe H, Morison L, et al. Lack of effectiveness of syndromic management in targeting vaginal infections in pregnancy in Entebbe, Uganda. *Sex Transm Infect* 2006; 82:285–9.
- Ong JJ, Magooa MP, Chikandiwa A, et al. Clinical characteristics of *Mycoplasma genitalium* and the usefulness of syndromic management among women living with human immunodeficiency virus. *Sex Transm Dis* 2019; 46:801–4.
- World Health Organization. Sexually transmitted infections (STIs). Available at: [https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-\(stis\)](https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)). Accessed 23 June 2022.
- Vargas S, Calvo G, Qquellon J, et al. Point-of-care testing for sexually transmitted infections in low-resource settings. *Clin Microbiol Infect* 2022; 28:946–51.
- Proctor G, Sarnar L, Symonds M. *Chlamydia* positive testing to treatment turnaround time (TAT) April to December 2016. *Sex Transm Infect* 2017; 93:A76.
- Geisler WM, Wang C, Morrison SG, Black CM, Banda CI, Hook EW, 3rd. The natural history of untreated *Chlamydia trachomatis* infection in the interval between screening and returning for treatment. *Sex Transm Dis* 2008; 35:119–23.
- Drain PK, Garrett NJ. The arrival of a true point-of-care molecular assay—ready for global implementation? *Lancet Glob Health* 2015; 3:e663–4.
- Huntington SE, Burns RM, Harding-Esch E, et al. Modelling-based evaluation of the costs, benefits and cost-effectiveness of multipathogen point-of-care tests for sexually transmitted infections in symptomatic genitourinary medicine clinic attendees. *BMJ Open* 2018; 8:e020394.
- Garrett N, Mtshali A, Osman F, et al. Impact of point-of-care testing and treatment of sexually transmitted infections and bacterial vaginosis on genital tract inflammatory cytokines in a cohort of young South African women. *Sex Transm Infect* 2021; 97:555–65.
- Garrett N, Mitchev N, Osman F, et al. Diagnostic accuracy of the Xpert CT/NG and OSOM *Trichomonas* rapid assays for point-of-care STI testing among young women in South Africa: a cross-sectional study. *BMJ Open* 2019; 9:e026888.
- Negash M, Wondmagegn T, Geremew D. Comparison of RPR and ELISA with TPHA for the diagnosis of syphilis: implication for updating syphilis point-of-care tests in Ethiopia. *J Immunol Res* 2018; 2018:1–7.
- Gaydos CA, Klausner JD, Pai NP, Kelly H, Coltart C, Peeling RW. Rapid and point-of-care tests for the diagnosis of *Trichomonas vaginalis* in women and men. *Sex Transm Infect* 2017; 93(Suppl 4):S31–5.
- Gray GE, Bekker LG, Laher F, et al. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. *N Engl J Med* 2021; 384:1089–100.
- Corporation S. Stata statistical software release 17. College Station, TX: StataCorp LLC, 2017.
- Hertz-Picciotto I, Rockhill B. Validity and efficiency of approximation methods for tied survival times in Cox regression. *Biometrics* 1997; 53:1151–6.
- Zhang Z, Reinikainen J, Adeleke KA, Pieterse ME, Groothuis-Oudshoorn CGM. Time-varying covariates and coefficients in Cox regression models. *Ann Transl Med* 2018; 6:121.
- Kuitunen I, Ponkilainen VT, Uimonen MM, Eskelinen A, Reito A. Testing the proportional hazards assumption in Cox regression and dealing with possible non-proportionality in total joint arthroplasty research: methodological perspectives and review. *BMC Musculoskelet Disord* 2021; 22:489.
- Wand H, Reddy T, Dassaye R, Moodley J, Naidoo S, Ramjee G. Estimating prevalence and incidence of sexually transmitted infections among South African women: implications of combined impacts of risk factors. *Int J STD AIDS* 2020; 31:1093–101.
- Morikawa E, Mudau M, Olivier D, et al. Acceptability and feasibility of integrating point-of-care diagnostic testing of sexually transmitted infections into a South African antenatal care program for HIV-infected pregnant women. *Infect Dis Obstet Gynecol* 2018; 2018:1–6.
- Myer L. Impact of on-site testing for maternal syphilis on treatment delays, treatment rates, and perinatal mortality in rural South Africa: a randomised controlled trial. *Sex Transm Infect* 2003; 79:208–13.
- Price CP. Point of care testing. *BMJ* 2001; 322: 1285–8.
- Huang W, Gaydos CA, Barnes MR, Jett-Goheen M, Blake DR. Comparative effectiveness of a rapid point-of-care test for detection of *Chlamydia trachomatis* among women in a clinical setting. *Sex Transm Infect* 2013; 89:108–14.
- Huppert J, Hesse E, Gaydos CA. What's the point? How point-of-care STI tests can impact infected patients. *Point Care* 2010; 9:36–46.
- Simeon K, Sharma M, Dorward J, et al. Comparative cost analysis of point-of-care versus laboratory-based testing to initiate and monitor HIV treatment in South Africa. *PLoS One* 2019; 14:e0223669.
- O'Kane MJ, McManus P, McGowan N, Lynch PL. Quality error rates in point-of-care testing. *Clin Chem* 2011; 57:1267–71.
- Kettler H, White K, Hawkes SJ; UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. Mapping the landscape of diagnostics for sexually transmitted infections: key findings and recommendations. Available at: <https://apps.who.int/iris/handle/10665/68990>. Accessed 27 June 2021.

CONFIDENCE IN DOVATO ACROSS TREATMENT SETTINGS⁴⁻⁹

Treatment-naïve resistance rates, with up to **3** years of evidence⁵⁻⁷

0%
(n=0/1,885)^{*4}
REAL-WORLD EVIDENCE

0.1%
(n=1/953)^{**1,11,5,5-7}
RANDOMISED CONTROLLED TRIALS

Treatment-experienced resistance rates, with up to **5** years of evidence¹⁻³

0.03%
(n=10/35,888)^{*4}
REAL-WORLD EVIDENCE

0%
(n=0/615)^{11,5,8,9}
RANDOMISED CONTROLLED TRIALS

>300,000 PEOPLE LIVING WITH HIV HAVE BEEN TREATED WITH DOVATO GLOBALLY¹⁰

DOVATO is supported by a wealth of evidence, with the outcomes of >40,000 people living with HIV captured within clinical trials and real-world evidence, including those with:^{4-9,11,12}



NO PRIOR TREATMENT EXPERIENCE¹³




NO BASELINE RESISTANCE TESTING¹³



HIGH BASELINE VIRAL LOAD
(>100,000 copies/mL and even >1M copies/mL)^{6,13}



LOW CD4 + COUNT
(≤200 cells/mm³)¹³



IS IT TIME TO RECONSIDER THE VALUE OF THE 2ND NRTI?

LEARN MORE 

DOVATO is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.¹³

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK on 0800 221441

REFERENCES

- Maggiolo F et al. BMC Infect Dis 2022; 22(1): 782.
- Taramasso L et al. AIDS Patient Care STDS 2021; 35(9): 342-353.
- Ciccullo A et al. JAIDS 2021; 88(3): 234-237.
- ViiV Healthcare. Data on File. REF-223795. 2024.
- Cahn P et al. AIDS 2022; 36(1): 39-48.
- Rolle C et al. Open Forum Infect Dis 2023; 10(3): ofad101.
- Cordova E et al. Poster presented at 12th IAS Conference on HIV Science. 23-26 July 2023. Brisbane, Australia. TUPEB02.
- De Wit S et al. Slides presented at HIV Glasgow. 23-26 October 2022. Virtual and Glasgow, UK. M041.
- Llibre J et al. Clin Infect Dis 2023; 76(4): 720-729.
- ViiV Healthcare. Data on File. REF-220949. 2024.
- Rolle C et al. Poster presented IDWeek. 11-15 October 2023. Virtual and Boston, USA. 1603.
- Slim J et al. Abstract presented IDWeek. 11-15 October 2023. Virtual and Boston, USA. 1593.
- DOVATO. Summary of Product Characteristics. June 2023.

PRESCRIBING INFORMATION

[Dovato Prescribing Information](#)

[Legal Notices](#)

[Privacy Policy](#)

[Contact Us](#)

ViiV Healthcare, 980 Great West Road, Brentford, Middlesex, London, UK.

ViiV trademarks are owned by or licensed to the ViiV Healthcare group of companies.

Non-ViiV trademarks are owned by or licensed to their respective owners or licensors.

©2024 ViiV Healthcare group of companies or its licensor. All rights reserved.

Intended for healthcare professionals only.

ABBREVIATIONS

3TC, lamivudine; **CD4**, cluster of differentiation 4; **DTG**, dolutegravir; **FDA**, United States Food and Drug Administration; **FTC**, emtricitabine; **HIV**, human immunodeficiency virus; **ITT-E**, intention-to-treat exposed; **NRTI**, nucleoside/nucleotide reverse transcriptase inhibitor; **RCT**, randomised controlled trial; **RNA**, ribonucleic acid; **TAF**, tenofovir alafenamide fumarate; **TDF**, tenofovir disoproxil fumarate; **XTC**, emtricitabine.

FOOTNOTES

*Data extracted from a systematic literature review of DTG+3TC real-world evidence. Overlap between cohorts cannot be fully excluded.

**The reported rate reflects the sum-total of resistance cases calculated from GEMINI I and II (n=1/716, through 144 weeks), STAT (n=0/131, through 52 weeks), and D2ARLING (n=0/106, through 24 weeks).⁵⁻⁷

†GEMINI I and II are two identical 148-week, phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority, controlled clinical trials testing the efficacy of DTG/3TC in treatment-naïve patients. Participants with screening HIV-1 RNA ≤500,000 copies/mL were randomised 1:1 to once-daily DTG/3TC (n=716, pooled) or DTG + TDF/FTC (n=717, pooled). The primary endpoint of each GEMINI study was the proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 48 (ITT-E population, snapshot algorithm).¹³

‡STAT is a phase IIIb, open-label, 48-week, single-arm pilot study evaluating the feasibility, efficacy, and safety of DTG/3TC in 131 newly diagnosed HIV-1 infected adults as a first line regimen. The primary endpoint was the proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 24.⁶

§D2ARLING is a randomised, open-label, phase IV study designed to assess the efficacy and safety of DTG/3TC in treatment-naïve people with HIV with no available baseline HIV-1 resistance testing. Participants were randomised in a 1:1 ratio to receive DTG/3TC (n=106) or DTG + TDF/XTC (n=108). The primary endpoint was the proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 48.⁷ Results at week 24 of the study.

|| The reported rate reflects the sum-total of resistance cases calculated from TANGO (n=0/369, through 196 weeks) and SALSA (n=0/246, through 48 weeks).^{8,9}

¶TANGO is a randomised, open-label, trial testing the efficacy of DOVATO in virologically suppressed patients. Participants were randomised in a 1:1 ratio to receive DOVATO (n=369) or continue with TAF-containing regimens (n=372) for up to 200 weeks. At Week 148, 298 of those on TAF-based regimens switched to DOVATO. The primary efficacy endpoint was the proportion of subjects with plasma HIV-1 RNA ≥50 copies/mL (virologic non-response) as per the FDA Snapshot category at Week 48 (adjusted for randomisation stratification factor).^{8,13}

#SALSA is a phase III, randomised, open-label, non-inferiority clinical trial evaluating the efficacy and safety of switching to DTG/3TC compared with continuing current antiretroviral regimens in virologically suppressed adults with HIV. Eligible participants were randomised 1:1 to switch to once-daily DTG/3TC (n=246) or continue current antiretroviral regimens (n=247). The primary endpoint was the proportion of subjects with plasma HIV-1 RNA ≥50 copies/mL at Week 48 (ITT-E population, snapshot algorithm).⁹